Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vectorite Biomedical's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$184.70 Mil. Vectorite Biomedical's average total tangible assets for the quarter that ended in Dec. 2025 was NT$460.22 Mil. Therefore, Vectorite Biomedical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 40.13%.
The historical rank and industry rank for Vectorite Biomedical's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4170'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -25.45 Med: -7.94 Max: 21.74
Current: 21.74
During the past 13 years, Vectorite Biomedical's highest Return-on-Tangible-Asset was 21.74%. The lowest was -25.45%. And the median was -7.94%.
ROCO:4170's Return-on-Tangible-Asset is ranked better than 95.69% of 1414
companies
in the Biotechnology industry
Industry Median: -36.16
vs ROCO:4170: 21.74
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vectorite Biomedical Return-on-Tangible-Asset Related Terms
Vectorite Biomedical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 40.13% mean?
Vectorite Biomedical (ROCO:4170) has a Return-on-Tangible-Asset of 40.13% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vectorite Biomedical and its competitors. According to the industry distribution chart, Vectorite Biomedical ranks #61 out of 1414 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Vectorite Biomedical's Return-on-Tangible-Asset too high?
Vectorite Biomedical's current Return-on-Tangible-Asset is 40.13%. Based on the distribution chart, Vectorite Biomedical ranks #61 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #61 out of 1414 companies for Return-on-Tangible-Asset. This places Vectorite Biomedical in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vectorite Biomedical and its competitors. Vectorite Biomedical's current Return-on-Tangible-Asset is 40.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.73, compared to a current price of NT$12.30 — trading 30.6% below its estimated fair value. The current Return-on-Tangible-Asset is 40.13%. Vectorite Biomedical's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Return-on-Tangible-Asset is 40.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.30 is trading 30.6% below its estimated GF Value™ of NT$17.73.
GuruFocus considers Vectorite Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:4170:
Return-on-Tangible-Asset: 40.13%
GF Value™: NT$17.73 vs. price of NT$12.30 (30.6% below fair value)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
64GF Score
Get the complete analysis for ROCO:4170
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
